Global economic outlook and risk appetite: The ongoing Middle East conflict and potential IMF downgrades of global growth forecasts could dampen overall market sentiment, leading investors to reduce exposure to higher-risk, clinical-stage biotech companies that are not yet profitable. This risk aversion impacts funding and valuation.

Interest rate environment and funding costs: As a clinical-stage biopharmaceutical company with significant R&D expenses, Biohaven relies on external funding. An environment of elevated interest rates, influenced by broader economic conditions, can increase the cost of capital, making it more expensive for the company to raise money through debt or equity, which could impact its operational runway and development programs.

Healthcare policy and regulatory environment: The biotechnology sector is highly sensitive to changes in healthcare policy, drug pricing regulations, and the U.S. FDA approval landscape. While not explicitly mentioned in the provided context, any shifts in these areas could have a profound impact on Biohaven's ability to bring its pipeline products to market and achieve profitability.